FDA Approves New Breast Implant

Earlier this month, the U.S. Food and Drug Administration (FDA) approved Allergan’s Natrelle Inspira SoftTouch breast implants, which provide a medium-firm gel option for women undergoing breast reconstruction, augmentation, or revision surgery. With this addition, the Natrelle line of breast implants is the only implant line with three levels of cohesive gel. "Adding Natrelle Inspira SoftTouch breast implants to our already robust line of offerings gives Allergan the most extensive variety of implants in the industry and provides doctors with a wide range of options," says David Nicholson, chief research and development officer of Allergan. "Now, the Inspira line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes. We're delighted to have this offering available in the U.S. since they are so popular with doctors and patients internationally."

Suggested Articles

Dermatologists are the leading influencers for cosmetic procedures and skincare choices.

Unrealistic expectations of self-image driven by social media lead to disappointed clients.

The FDA granted Erchonia 510(k) market clearance to market its EVRL for the temporary relief of chronic neck and shoulder pain.